The drug is intended to be used alone or in combination with semaglutide (CagriSema
GLP-1s and SGLT2s: The New Power Players in Diabetes Care By 2024, more Medicare patients with T2D are sticking with GLP-1 or SGLT2 therapies as their sole treatment, doubling since 2020
But the availability of GLP-1 injectables is rapidly changing, too
Other common, and often minor, side effects can include headache, fatigue, dizziness, irritation around the injection site, and general lack of energy
A personalized plan is provided after consultation
Still, results should be carefully generalized to cases of background kidney dysfunction or when using drugs with narrow therapeutic index